Abstract
Oral agents are clearly popular with patients in the battle for glycemic control. Significant recent advances in oral agents have provided several interesting and synergistic medications to make glycemic control more attainable. These newer agents, which address the three causes of hyperglycemia in the type 2 diabetic state, can be used synergistically with enhanced glycemic control.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Luna B, Feinglos MN. (2001) Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician 63:1747–1756.
Mudaliar S, Henry RR. (2001) New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 52:239–257.
Ahmann AJ, Riddle MC. (2000) Oral pharmacological agents. In: Medical Management of Diabetes Mellitus. New York, NY: Marcel Dekker, pp. 267–283.
DeFronzo RA. (1999) Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 133:73–74.
United Kingdom Prospective Diabetes Study (UKPDS) Group. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853.
Malmberg K, Ryden L, Efendic S, et al. (1995) Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26:57–65.
United Kingdom Prospective Diabetes Study (UKPDS) Group. (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865.
Codario R. (2003) A guide to combination therapy in type 2 diabetes. Patient Care 37:16–24.
Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. (2000) Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660–1665.
Dude DS, Peiris AN. (2002) Concise update to managing adult diabetes. South Med J 95:4–9.
Izucchi SE. (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360–372.
Fontbonne A, Charles MA, Juhan-Vague I, Bard MM, Andre P, Isnard F. (1996) The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 19:920–926.
DeFronzo RA, Goodman AM. (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333:541–549.
Reaven GM, Johnstone P, Hollenbeck CB, et al. (1992) Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 74:1020–1026.
Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. (2001) Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134:61–71.
Malinowski JM, Bolesta S. (2000) Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 22:1151–1168.
Lebovitz HE, Kreider M, Freed MI. (2002) Evaluatin of liver funciton in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25:815–821.
Yamasaki Y, Kawamori R, Wasada T, et al. (1997) Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. Tohoku J Exp Med 183:173–183.
Moses R, Slobodniuk R, Boyages S, et al. (1999) Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 22:119–124.
Hanefield M, Bouter KP, Dickinson S, Guitard C. (2000) Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 23:202–207.
Bell DS, Ovalle F. (2002) Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract 8:271–275.
Dailey GE. (2004) Improving oral pharmacologic treatment and management of type 2 diabetes. Manag Care 13:41–47.
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
(2005). Oral Agents for Type 2 Diabetes. In: Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. Current Clinical Practice. Humana Press. https://doi.org/10.1385/1-59259-932-X:75
Download citation
DOI: https://doi.org/10.1385/1-59259-932-X:75
Publisher Name: Humana Press
Print ISBN: 978-1-58829-471-5
Online ISBN: 978-1-59259-932-5
eBook Packages: MedicineMedicine (R0)